New Antimicrobials Targeting Bacterial RNA Polymerase Holoenzyme Assembly Identified with an in Vivo BRET-Based Discovery Platform
Authors:
- Sara SartiniSSSara Sartini
- Elisabetta LevatiELElisabetta Levati
- Martina MaccesiMMMartina Maccesi
- Matteo GuerraMGMatteo Guerra
- Gilberto SpadoniGSGilberto Spadoni
- Stéphane BachStéphane Bach
- Monica BenincasaMBMonica Benincasa
- Marco ScocchiMSMarco Scocchi
- Simone OttonelloSOSimone Ottonello
- Silvia RivaraSRSilvia Rivara
- Barbara MontaniniBMBarbara Montanini
- 16 July 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 14 (8) , 1727-1736
Abstract
Bacterial resistance represents a major health threat worldwide, and the development of new therapeutics, including innovative antibiotics, is urgently needed. We describe a discovery platform, centered on in silico screening and in vivo bioluminescence resonance energy transfer in yeast cells, for the identification of new antimicrobials that, by targeting the protein–protein interaction between the β′-subunit and the initiation factor σ70 of bacterial RNA polymerase, inhibit holoenzyme assembly and promoter-specific transcription. Out of 34 000 candidate compounds, we identified seven hits capable of interfering with this interaction. Two derivatives of one of these hits proved to be effective in inhibiting transcription in vitro and growth of the Gram-positive pathogens Staphylococcus aureus and Listeria monocytogenes. Upon supplementation of a permeability adjuvant, one derivative also effectively inhibited Escherichia coli growth. On the basis of the chemical structures of these inhibitors, we generated a ligand-based pharmacophore model that will guide the rational discovery of increasingly effective antibacterial agents.Keywords
Funding Information
- Universit? degli Studi di Parma
- Regione Emilia-Romagna (PRUa1RI-2012-006)
This publication has 34 references indexed in Scilit:
- Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3)Molecular Cell, 2018
- Fidaxomicin jams Mycobacterium tuberculosis RNA polymerase motions needed for initiation via RbpA contactseLife, 2018
- Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA PolymeraseCell, 2017
- New approaches to antimicrobial discoveryBiochemical Pharmacology, 2017
- Antimicrobial ResistanceJAMA, 2016
- Antibacterial drug discovery in the resistance eraNature, 2016
- Rifamycins – Obstacles and opportunitiesTuberculosis, 2010
- Call of the wild: antibiotic resistance genes in natural environmentsNature Reviews Microbiology, 2010
- Structures of RNA polymerase–antibiotic complexesCurrent Opinion in Structural Biology, 2009
- Structural Mechanism for Rifampicin Inhibition of Bacterial RNA PolymeraseCell, 2001